Natalie E. Mccormick

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice?

The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice?

Journal: The Lancet. Rheumatology

Published: May 13, 2026

Exploring Information Needs and Perspectives on a Patient Decision Aid for Biologic Therapy: A Qualitative Interview Study Among Individuals with Rheumatoid Arthritis.

Exploring Information Needs and Perspectives on a Patient Decision Aid for Biologic Therapy: A Qualitative Interview Study Among Individuals with Rheumatoid Arthritis.

Journal: Patient preference and adherence

Published: October 04, 2025

Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.

Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.

Journal: Diabetes care

Published: July 21, 2025

Reply.

Reply.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 18, 2025

Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial Emulations.

Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial Emulations.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 30, 2025

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.

Journal: BMJ (Clinical research ed.)

Published: October 30, 2024

Proinflammatory Dietary Pattern and the Risk of Female Gout: Sex-Specific Findings From Three Prospective Cohort Studies.

Proinflammatory Dietary Pattern and the Risk of Female Gout: Sex-Specific Findings From Three Prospective Cohort Studies.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 23, 2024

Long-Term Lignan Intake, Whole Grain Foods, and the Risk of Gout: Results From Two Prospective Cohort Studies.

Long-Term Lignan Intake, Whole Grain Foods, and the Risk of Gout: Results From Two Prospective Cohort Studies.

Journal: Arthritis care & research

Published: October 16, 2024

Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.

Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.

Journal: The Lancet. Rheumatology

Published: June 21, 2024

Recurrent Gout and Serum Urate-Reply.

Recurrent Gout and Serum Urate-Reply.

Journal: JAMA

Published: May 02, 2024

Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.

Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.

Journal: JAMA internal medicine

Published: April 15, 2024

Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.

Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.

Journal: PloS one

Published: March 22, 2024

Showing 1-12 of 66

Last Updated: 09/26/2026